v3.25.2
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):
Three Months Ended June 30,
Six Months Ended June 30,
2025202420252024
Collaborative arrangement revenue$1,373 $1,141 $2,854 $2,155 
Less:
OCU4001,998 2,180 3,843 3,699 
OCU410 and OCU410ST1,117 1,197 2,295 1,681 
NeoCart8 28 5 355 
COVAXIN— 56 — 73 
Inhaled mucosal vaccine platform131 807 319 1,496 
OCU200151 92 400 277 
Unallocated costs:
Research and development personnel costs4,091 3,164 8,106 5,844 
Facilities and other support costs834 879 1,815 1,377 
Other72 499 1,149 926 
Total research and development8,402 8,902 17,932 15,728 
General and administrative6,766 7,688 13,218 14,092 
Total operating expenses15,168 16,590 31,150 29,820 
Loss from operations(13,795)(15,449)(28,296)(27,665)
Interest (expense) income, net(1,058)173 (1,972)475 
Other income (expense), net114 (4)179 (14)
Segment and consolidated net loss$(14,739)$(15,280)$(30,089)$(27,204)